Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Black Diamond Therapeutics, a precision oncology medicine company, announced that its CEO, David M. Epstein, Ph.D., will present an update on the company's progress at the H.C. Wainwright Global Investment Conference. The presentation will be available for on-demand viewing starting May 24, 2022, at 7:00 a.m. ET. Interested parties can access the webcast in the investor relations section of the company’s website, where a replay will also be available for 90 days. The company focuses on developing MasterKey therapies for genetically defined cancers.

CAMBRIDGE, Mass. and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the H.C. Wainwright Global Investment Conference. The presentation will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. ET.

A webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived on the site for 90 days.

About Black Diamond

Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies. Black Diamond is addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options. Black Diamond is built upon a deep understanding of cancer genetics, onco-protein function, and drug discovery. The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data to predict and validate oncogenic mutations that promote cancer across tumor types as MasterKey mutations. Black Diamond discovers and develops selective MasterKey therapies against these families of oncogenic mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts
For Investors:
Julie Seidel
investors@bdtx.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com

FAQ

What is Black Diamond Therapeutics presenting at the H.C. Wainwright Global Investment Conference?

Black Diamond Therapeutics will have its CEO, David M. Epstein, present an update on the company's progress.

When can I watch the Black Diamond Therapeutics presentation?

The on-demand presentation will be available starting May 24, 2022, at 7:00 a.m. ET.

Where can I access the webcast of the Black Diamond Therapeutics presentation?

The webcast can be accessed in the investor relations section of Black Diamond Therapeutics' website.

How long will the Black Diamond Therapeutics presentation be available for replay?

The replay of the webcast will be available for 90 days after the presentation.

What does Black Diamond Therapeutics focus on?

The company specializes in developing precision oncology therapies for patients with genetically defined cancers.